S
Skye Bioscience, Inc. (SKYE)
NGM – Real Time Price. Currency in USD
0.81
-0.07 (-7.56%)
At close: May 12, 2026, 4:00 PM EDT
0.81
-0.00 (-0.42%)
After-hours: May 12, 2026, 7:46 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
0.81
-0.07 (-7.56%)
At close: May 12, 2026, 4:00 PM EDT
0.81
-0.00 (-0.42%)
After-hours: May 12, 2026, 7:46 PM EDT
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
| Mr. John P. Sharp CPA | CFO and Principal Financial & Accounting Officer |
| Mr. Punit S. Dhillon B.A. | President, CEO & Director |
| Mr. Tu Diep M.Sc. | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-16 | DEFA14A | skye20260416-proxycarddefa.htm |
| 2026-04-16 | DEF 14A | skye-20260415.htm |
| 2026-04-06 | PREM14A | skye_20260403xproxyxprelim.htm |
| 2026-04-06 | PRE 14A | skye_20260406xproxyxprelim.htm |
| 2026-04-06 | 8-K/A | skye-20260331.htm |
| 2026-04-03 | 8-K | skye-20260331.htm |
| 2026-03-19 | 8-K | skye-20260317.htm |
| 2026-03-11 | S-8 | skye-03102026_sx8evergreen.htm |
| 2026-03-10 | 8-K | skye-20260310.htm |
| 2026-03-10 | 10-K | skye-20251231.htm |